AbbVie Development Partner Hits Back At $31M FTC Penalty
A testosterone replacement therapy development partner of AbbVie Inc. told the Third Circuit late Wednesday that it should deny an appeal from the U.S. Federal Trade Commission seeking increased disgorgement of...To view the full article, register now.
Already a subscriber? Click here to view full article